title: Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy.
abstract: BACKGROUND
  Alcohol septal ablation (ASA) reduces left ventricular outflow tract (LVOT) pressure gradient in patients with hypertrophic obstructive cardiomyopathy (HOCM), which leads to left ventricular remodeling. We sought to describe the early to midterm changes and modulating factors of the remodeling process using cardiac MRI (CMR).
  
  
  RESULTS
  CMR was performed at baseline and 1 and 6 months after ASA in 29 patients with HOCM (age 52+/-16 years). Contrast-enhanced CMR showed no infarct-related hyperenhancement outside the target septal area. Septal mass decreased from 75+/-23 g at baseline to 68+/-22 and 58+/-19 g (P<0.001) at 1- and 6-month follow-up, respectively. Remote, nonseptal mass decreased from 141+/-41 to 132+/-40 and 111+/-27 g (P<0.001), respectively. Analysis of temporal trends revealed that septal mass reduction was positively associated with contrast-enhanced infarct size and transmural or left-sided septal infarct location at both 1 and 6 months. Remote mass reduction was associated with infarct location at 6 months but not with contrast-enhanced infarct size. By linear regression analysis, percentage remote mass reduction correlated significantly with LVOT gradient reduction at 6-month follow-up (P=0.03).
  
  
  CONCLUSIONS
  Left ventricular remodeling after ASA occurs early and progresses on midterm follow-up, modulated by CMR infarct size and location. Remote mass reduction is associated with infarct location and correlates with reduction of the LVOT pressure gradient. Thus, myocardial hypertrophy in HOCM is, at least in part, afterload dependent and reversible and is not exclusively caused by the genetic disorder.
authors.affiliation: Department of Cardiology, VU University Medical Center, Amsterdam, The Netherlands. wg.vandockum@vumc.nl
authors.forename: Willem G
authors.initials: WG
authors.lastname: van Dockum
authors.forename: Aernout M
authors.initials: AM
authors.lastname: Beek
authors.forename: Folkert J
authors.initials: FJ
authors.lastname: ten Cate
authors.forename: Jurrien M
authors.initials: JM
authors.lastname: ten Berg
authors.forename: Olga
authors.initials: O
authors.lastname: Bondarenko
authors.forename: Marco J W
authors.initials: MJ
authors.lastname: Götte
authors.forename: Jos W R
authors.initials: JW
authors.lastname: Twisk
authors.forename: Mark B M
authors.initials: MB
authors.lastname: Hofman
authors.forename: Cees A
authors.initials: CA
authors.lastname: Visser
authors.forename: Albert C
authors.initials: AC
authors.lastname: van Rossum
mesh_terms: D000328:Adult; D000368:Aged; D002312:Cardiomyopathy, Hypertrophic / Q000628:therapy*; D000431:Ethanol / Q000627:therapeutic use*; D005260:Female; D006346:Heart Septum / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000139:chemically induced / Q000473:pathology; D016896:Treatment Outcome; D020257:Ventricular Remodeling
chemical_list: D000431:Ethanol